We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Modafinil potentially increases the risk of congenital malformations when used in pregnancy. Modafinil should not be used during pregnancy and women of childbearing potential must use effective contraception during treatment and for 2 months after stopping modafinil.
The review of the safety of isotretinoin has concluded.
Further information is available to support safer use
Being honest and transparent with online reviews and endorsements, including on social media and in other online content.
Review of the evidence of misuse and harm in relation to the benzofuran-type substances.
Information and documents on Public Health England’s review of the evidence for dependence on, and withdrawal from, prescribed medicines.
How to use feedback from marketplace reviews to evaluate your digital health product.
How businesses should comply with consumer protection law on consumer reviews.
A review of MDMA (‘ecstasy’), its harms and classification under the Misuse of Drugs Act 1971 (2009). The Advisory Council on the Misuse of…
Do not include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).